Roswell Park Research Ties In With World No Tobacco Day 2009
June 1st, 2009 by admin
Posted in Other news | No Comments »
Novel Drug Shows Promising Results in Early Clinical Trials
June 1st, 2009 by admin
BUFFALO, NY- A new cancer drug shows promising results in patients with metastatic cancer. The phase I clinical trial research will be presented by Alex A. Adjei, MD, PhD, Senior Vice President for Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park Cancer Institute (RPCI), at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.
Posted in Other news | No Comments »
New Drug Combination Offers Novel Treatment Strategy for Non-Hodgkin's Lymphoma
June 1st, 2009 by admin
BUFFALO, NY- Patients diagnosed with non-Hodgkin’s lymphoma who become resistant to standard therapies may have a new treatment option. Scientists in the Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute analyzed the mechanisms to overcome treatment resistance, including a new drug combination. Francisco J. Hernandez-Ilizaliturri, MD, Departments of Medicine and Immunology, Roswell Park Cancer Institute (RPCI), will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.
Posted in Other news | No Comments »
Study Evaluates Ability of Drug to Overcome Resistance to Standard Colorectal Cancer Therapy
June 1st, 2009 by admin
BUFFALO, NY- Roswell Park scientists are investigating a new combination of drugs for colorectal cancer patients who have become intolerant or resistant to standard therapies. Marwan Fakih, MD, Department of Medicine at Roswell Park Cancer Institute will present the results of a phase I clinical study at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.
Posted in Colorectal Cancer | No Comments »
New Treatment Combination Proves Safe, Potentially Effective for Head and Neck Cancer Patients, UPCI Researchers Find
June 1st, 2009 by admin
PITTSBURGH, May 30, 2009 – Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, MD, associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI). The results will be disclosed at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) on May 30 in Orlando, Fla.
Posted in Other news | No Comments »
Newly Identified Genes May Help Improve Treatment for Melanoma Patients, Pitt Study Finds
June 1st, 2009 by admin
PITTSBURGH, May 30, 2009 – Researchers from the University of Pittsburgh Cancer Institute (UPCI) have identified eight genes that help predict a melanoma patient's response to treatment. The new findings are being presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO), May 29 to June 2, in Orlando, Fla.
Posted in Melanoma | No Comments »
Minimally Invasive Surgery for Esophageal Cancer Reduces Mortality Rates, Length of Hospital Stays
June 1st, 2009 by admin
ORLANDO, May 31, 2009 – Patients with esophageal cancer who require surgery may benefit from having minimally invasive surgery instead of an open esophagectomy, or removal of the esophagus, according to a University of Pittsburgh Cancer Institute (UPCI) phase II study. The results will be presented May 31 at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla.
Posted in Other news | No Comments »